Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.5 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 0.95% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 13.21% YoY) and the FY2025 annual result came in at $1.5 billion, up 34.19% from the prior year.
• Liabilities and Shareholders Equity held at $1.5 billion in Q1 2026 per BEAM's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.5 billion in Q4 2025 and bottomed at $1.1 billion in Q4 2024.
• The 5-year median for Liabilities and Shareholders Equity is $1.4 billion (2023), against an average of $1.4 billion.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity surged 109.65%; it then declined 24.38% in 2024.
• Tracing BEAM's Liabilities and Shareholders Equity over 5 years: stood at $1.3 billion in 2022, then grew by 8.79% to $1.5 billion in 2023, then declined by 24.38% to $1.1 billion in 2024, then jumped by 34.19% to $1.5 billion in 2025, then retreated by 0.03% to $1.5 billion in 2026.
• Per Business Quant, the three latest BEAM Liabilities and Shareholders Equity figures stand at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.3 billion (Q3 2025).

Peer Comparison